Results 21 to 30 of about 26,115 (197)

Methylphenidate treatment for cognitive symptoms associated with ADHD in a pediatric epilepsy patient following resection of a left frontal cortical dysplasia

Epilepsy & Behavior Reports, 2021
We present data on a 10-year-old patient with drug-resistant epilepsy who was treated with methylphenidate for symptoms of attention deficit hyperactivity disorder (ADHD) that developed after she underwent surgical resection of a left frontal cortical ...
Donald J. Bearden, Sidra Shakil, David O'Banion, Kim E. Ono, Daniel L. Drane, David W. Loring, Daniel C. Tarquinio   +6 more
doaj   +1 more source

Stability of Methylphenidate under Various pH Conditions in the Presence or Absence of Gut Microbiota

Pharmaceuticals, 2021
Methylphenidate is one of the most widely used oral treatments for attention-deficit/hyperactivity disorder (ADHD). The drug is mainly absorbed in the small intestine and has low bioavailability.
Julia Aresti-Sanz, Markus Schwalbe, Rob Rodrigues Pereira, Hjalmar Permentier, Sahar El Aidy   +4 more
doaj   +1 more source

Prevalence of methylphenidate use by university students in Campos dos Goytacazes, RJ

Vértices, 2014
Methylphenidate is a central nervous system stimulant commonly prescribed for children with Attention Deficit Hyperactivity Disorder. The aim of this study was to identify the prevalence of methylphenidate users among college students, as well as the ...
Fernanda Fraga Pessanha, Jéssica da Silva Mota   +1 more
doaj   +1 more source

Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder [PDF]

, 2014
A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response
Esther Cardo, Hodgkins, P, Dittmann, RW, Caballero, B, Beatriz Caballero, Cardo, E, Adeyi, Ben, Civil, R, Ben Adeyi, Anderson, CS, Civil, Richard, Colleen S. Anderson, Hodgkins, Paul, Cardo-Jalon, Esther, Coghill, DR, Nagy, Peter, Cardo, Esther, Richard Civil, David R. Coghill, Anderson, Colleen S., Adeyi, B, Coghill, David R., Dittmann, Ralf W., Peter Nagy, Nagy, P, Caballero, Beatriz, Ralf W. Dittmann, Paul Hodgkins   +27 more
core   +1 more source

Reward‐enhancing effect of methylphenidate is abolished in dopamine transporter knockout mice: A model of attention‐deficit/hyperactivity disorder

Neuropsychopharmacology Reports, 2018
Aim Attention‐deficit/hyperactivity disorder is a heterogeneous neurobiological disorder that is characterized by inattention, impulsivity, and an increase in motor activity.
Soichiro Ide, Yuiko Ikekubo, Jennifer Hua, Yukio Takamatsu, George R. Uhl, Ichiro Sora, Kazutaka Ikeda   +6 more
doaj   +1 more source

HPLC determination of methylphenidate and its metabolite, ritalinic acid, by high-performance liquid chromatography with peroxyoxalate chemiluminescence detection. [PDF]

, 2011
An HPLC-peroxyoxalate chemiluminescence (PO-CL) method for simultaneous determination of methylphenidate (MPH) and ritalinic acid (RA) was developed. The method was used to monitor MPH and RA after administration of MPH to rats.
Rie Ikeda, Kuroda, Naotaka, Wada, Mitsuhiro, Kikura-Hanajiri, Ruri, Abe, Keisuke, Nakashima, Kenichiro, Ikeda, Rie, Kenichiro Nakashima, Mitsuhiro Wada, Ruri Kikura-Hanajiri, Naotaka Kuroda, Keisuke Abe   +11 more
core   +1 more source

Effect of methylphenidate in patients with cancer-related fatigue: a systematic review and meta-analysis.

PLoS ONE, 2014
BackgroundCancer-related fatigue (CRF) is a common symptom affecting patients with cancer. There are an increasing number of trials examining potential treatments for CRF.
Shun Gong, Ping Sheng, Hai Jin, Hua He, Enbo Qi, Wen Chen, Yan Dong, Lijun Hou   +7 more
doaj   +1 more source

Methylphenidate remediates aberrant brain network dynamics in children with attention‐deficit/hyperactivity disorder: A randomized controlled trial

NeuroImage, 2022
Methylphenidate is a widely used first-line treatment for attention deficit/hyperactivity disorder (ADHD), but the underlying circuit mechanisms are poorly understood.
Yoshifumi Mizuno, Weidong Cai, Kaustubh Supekar, Kai Makita, Shinichiro Takiguchi, Akemi Tomoda, Vinod Menon   +6 more
doaj   +1 more source

Adverse reactions of Methylphenidate in children with attention deficit-hyperactivity disorder: Report from a referral center

Journal of Research in Pharmacy Practice, 2014
Objective: The aim of the current study was to determine various aspects of methylphenidate adverse reactions in children with attention deficit-hyperactivity disorder (ADHD) in Iran.
Zahra Khajehpiri, Javad Mahmoudi-Gharaei, Toktam Faghihi, Iman Karimzadeh, Hossein Khalili, Mostafa Mohammadi   +5 more
doaj   +1 more source

ADHD diagnosis and methylphenidate consumption in children and adolescents: A systematic analysis of health databases in France over the period 2010–2019

Frontiers in Psychiatry, 2022
ContextADHD is the most common mental disorder in school-aged children. In France, methylphenidate is the only drug authorized for ADHD. Here, we describe the pattern of ADHD diagnosis and methylphenidate prescription to children and adolescents from ...
Sébastien Ponnou, Benoît Thomé
doaj   +1 more source